FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2100048077> ?p ?o ?g. }

• W2100048077 endingPage "2214" @default.
• W2100048077 startingPage "2203" @default.
• W2100048077 abstract "Abstract Erlotinib is a tyrosine kinase inhibitor approved for the treatment of patients with advanced non–small cell lung cancer (NSCLC). In these patients, erlotinib prolongs survival but its benefit remains modest because many tumors express wild-type (wt) EGFR or develop a second-site EGFR mutation. To test drug combinations that could improve the efficacy of erlotinib, we combined erlotinib with quinacrine, which inhibits the FACT (facilitates chromatin transcription) complex that is required for NF-κB transcriptional activity. In A549 (wtEGFR), H1975 (EGFR-L858R/T790M), and H1993 (MET amplification) NSCLC cells, this drug combination was highly synergistic, as quantified by Chou–Talalay combination indices, and slowed xenograft tumor growth. At a sub-IC50 but more clinically attainable concentration of erlotinib, quinacrine, alone or in combination with erlotinib, significantly inhibited colony formation and induced cell-cycle arrest and apoptosis. Quinacrine decreased the level of active FACT subunit SSRP1 and suppressed NF-κB–dependent luciferase activity. Knockdown of SSRP1 decreased cell growth and sensitized cells to erlotinib. Moreover, transcriptomic profiling showed that quinacrine or combination treatment significantly affected cell-cycle–related genes that contain binding sites for transcription factors that regulate SSRP1 target genes. As potential biomarkers of drug combination efficacy, we identified genes that were more strongly suppressed by the combination than by single treatment, and whose increased expression predicted poorer survival in patients with lung adenocarcinoma. This preclinical study shows that quinacrine overcomes erlotinib resistance by inhibiting FACT and cell-cycle progression, and supports a clinical trial testing erlotinib alone versus this combination in advanced NSCLC. Mol Cancer Ther; 13(9); 2203–14. ©2014 AACR." @default.
• W2100048077 created "2016-06-24" @default.
• W2100048077 creator A5015550222 @default.
• W2100048077 creator A5016353084 @default.
• W2100048077 creator A5035744404 @default.
• W2100048077 creator A5036383068 @default.
• W2100048077 creator A5036587861 @default.
• W2100048077 creator A5058391665 @default.
• W2100048077 creator A5066125347 @default.
• W2100048077 creator A5090427988 @default.
• W2100048077 date "2014-09-01" @default.
• W2100048077 modified "2023-10-13" @default.
• W2100048077 title "Quinacrine Overcomes Resistance to Erlotinib by Inhibiting FACT, NF-κB, and Cell-Cycle Progression in Non–Small Cell Lung Cancer" @default.
• W2100048077 cites W1796594401 @default.
• W2100048077 cites W1964272901 @default.
• W2100048077 cites W1967394241 @default.
• W2100048077 cites W1969334180 @default.
• W2100048077 cites W1980497534 @default.
• W2100048077 cites W2002191849 @default.
• W2100048077 cites W2003984225 @default.
• W2100048077 cites W2031019010 @default.
• W2100048077 cites W2043696829 @default.
• W2100048077 cites W2050237811 @default.
• W2100048077 cites W2055133892 @default.
• W2100048077 cites W2055878807 @default.
• W2100048077 cites W2077945404 @default.
• W2100048077 cites W2080669049 @default.
• W2100048077 cites W2087955215 @default.
• W2100048077 cites W2093613683 @default.
• W2100048077 cites W2096439168 @default.
• W2100048077 cites W2096564318 @default.
• W2100048077 cites W2097026987 @default.
• W2100048077 cites W2101142880 @default.
• W2100048077 cites W2112739348 @default.
• W2100048077 cites W2113833510 @default.
• W2100048077 cites W2126496132 @default.
• W2100048077 cites W2135836172 @default.
• W2100048077 cites W2138297714 @default.
• W2100048077 cites W2154026654 @default.
• W2100048077 cites W2157320227 @default.
• W2100048077 cites W2158217645 @default.
• W2100048077 cites W2168303063 @default.
• W2100048077 cites W2169048194 @default.
• W2100048077 cites W2171530299 @default.
• W2100048077 cites W2341769195 @default.
• W2100048077 doi "https://doi.org/10.1158/1535-7163.mct-14-0013" @default.
• W2100048077 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4156551" @default.
• W2100048077 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/25028470" @default.
• W2100048077 hasPublicationYear "2014" @default.
• W2100048077 type Work @default.
• W2100048077 sameAs 2100048077 @default.
• W2100048077 citedByCount "56" @default.
• W2100048077 countsByYear W21000480772015 @default.
• W2100048077 countsByYear W21000480772016 @default.
• W2100048077 countsByYear W21000480772017 @default.
• W2100048077 countsByYear W21000480772018 @default.
• W2100048077 countsByYear W21000480772019 @default.
• W2100048077 countsByYear W21000480772020 @default.
• W2100048077 countsByYear W21000480772021 @default.
• W2100048077 countsByYear W21000480772022 @default.
• W2100048077 countsByYear W21000480772023 @default.
• W2100048077 crossrefType "journal-article" @default.
• W2100048077 hasAuthorship W2100048077A5015550222 @default.
• W2100048077 hasAuthorship W2100048077A5016353084 @default.
• W2100048077 hasAuthorship W2100048077A5035744404 @default.
• W2100048077 hasAuthorship W2100048077A5036383068 @default.
• W2100048077 hasAuthorship W2100048077A5036587861 @default.
• W2100048077 hasAuthorship W2100048077A5058391665 @default.
• W2100048077 hasAuthorship W2100048077A5066125347 @default.
• W2100048077 hasAuthorship W2100048077A5090427988 @default.
• W2100048077 hasBestOaLocation W21000480771 @default.
• W2100048077 hasConcept C121608353 @default.
• W2100048077 hasConcept C126322002 @default.
• W2100048077 hasConcept C143998085 @default.
• W2100048077 hasConcept C185592680 @default.
• W2100048077 hasConcept C2776256026 @default.
• W2100048077 hasConcept C2777930144 @default.
• W2100048077 hasConcept C2778087573 @default.
• W2100048077 hasConcept C2779438470 @default.
• W2100048077 hasConcept C2780580887 @default.
• W2100048077 hasConcept C29537977 @default.
• W2100048077 hasConcept C502942594 @default.
• W2100048077 hasConcept C55493867 @default.
• W2100048077 hasConcept C62112901 @default.
• W2100048077 hasConcept C71924100 @default.
• W2100048077 hasConcept C86803240 @default.
• W2100048077 hasConcept C98274493 @default.
• W2100048077 hasConceptScore W2100048077C121608353 @default.
• W2100048077 hasConceptScore W2100048077C126322002 @default.
• W2100048077 hasConceptScore W2100048077C143998085 @default.
• W2100048077 hasConceptScore W2100048077C185592680 @default.
• W2100048077 hasConceptScore W2100048077C2776256026 @default.
• W2100048077 hasConceptScore W2100048077C2777930144 @default.
• W2100048077 hasConceptScore W2100048077C2778087573 @default.
• W2100048077 hasConceptScore W2100048077C2779438470 @default.
• W2100048077 hasConceptScore W2100048077C2780580887 @default.
• W2100048077 hasConceptScore W2100048077C29537977 @default.
• W2100048077 hasConceptScore W2100048077C502942594 @default.

• next